))
The Economics of Ozempic & Other Weight Loss Drugs: A Deep Dive with Ben Ippolito
Manage episode 419171214 series 3439064
Contenido proporcionado por DC EKG and Evergreen Podcasts | Big Whig Media. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente DC EKG and Evergreen Podcasts | Big Whig Media o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Join hosts Joe Grogan and Eric Ueland on DC EKG as they delve into the complexities of health economics in America with special guest Ben Ippolito. In this episode, they explore the skyrocketing prices of GLP-1 weight loss drugs and discuss the potential for Medicare coverage. Ben Ippolito sheds light on the current prohibition against Medicare covering weight loss drugs, the shift from viewing obesity as a cosmetic issue to recognizing it as a clinical outcome, and the high out-of-pocket expenses people are willing to pay. Ben also examines the business implications for pharmaceutical companies if Medicare covers these drugs, the impact of price caps under the IRA, and the competitive challenges new market entrants face.
--LINKS--
Follow DC EKG: https://twitter.com/DCEKGpodcast
Follow Ben: https://twitter.com/ben_ippolito
82 episodios
Compartir
